Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
University of Oklahoma
100 participants
Nov 30, 2023
INTERVENTIONAL
Conditions
Summary
This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.
Eligibility
Inclusion Criteria3
- Ages 5-17 years old
- Presents to the ED with a respiratory score in the "Moderate" range (6
- Parent(s)/Caregiver(s) speak English
Exclusion Criteria3
- Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients
- Patients who are pregnant
- Parent(s)/Caregiver(s) do not speak English
Interventions
The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension. 15-19 kg: 750 mg 20-29 kg: 1000 mg 30-39 kg: 1500 mg \>40 kg: 2000 mg
The control group will not receive IV magnesium sulfate within the first hour of treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06137040